Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

DC-based therapeutic glioma vaccine and preparation method thereof

A glioma and therapeutic vaccine technology, applied in the fields of bioengineering and biomedicine, can solve the problems of glioma vaccines such as unstable properties, low specificity, and weak immunogenicity, and improve liver immune tolerance Receptivity, immunogenicity and specificity, good regulation effect

Inactive Publication Date: 2016-01-13
SHEN ZHEN ISTEM REGENERATIVE MEDICINE SCI TECH CO LTD
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The technical problem to be solved by the present invention is to provide a DC-based vaccine with strong immunogenicity and specificity in view of the defects in the prior art of glioma vaccines, such as unstable properties, weak immunogenicity, and low specificity. Glioma Therapeutic Vaccines

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • DC-based therapeutic glioma vaccine and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0023] A DC-based glioma therapeutic vaccine provided by the present invention, its preparation method comprises the following steps:

[0024] (1) Obtain immature DC;

[0025] (2) Adding glioma antigen polypeptide to co-culture with immature DC;

[0026] (3) Add tumor necrosis factor-α and interleukin or lipopolysaccharide and continue to culture for 7-13 days, until DC matures and DC is loaded with glioma antigen polypeptide.

[0027] In step (1), immature DCs can be derived from human blood, but because immature DCs only account for 0.5-1.0% of the total number of monocytes in the blood, the number is very small; therefore, in a preferred embodiment of the present invention, induction The method of mononuclear cells to obtain immature DC, the specific steps are:

[0028] (11) isolate monocytes from blood;

[0029] (12) Add in vitro induction medium and cultivate for 72h, and the monocytes obtained in step (11) are amplified;

[0030] (13) Perform a half-quantity exchange...

Embodiment 1

[0048] The preparation method of DC-based glioma therapeutic vaccine comprises the following steps:

[0049] 1) Take 20ml of human peripheral blood, and use Ficon Lymphocyte Separation Medium to separate CD14 + Monocytes, after washing with PBS solution, press 2.5-5x10 7 / 3ml / well was inoculated in a six-well plate, and incubated with RPMI-1640 medium at 37°C, 5% CO 2 placed in an incubator for 90 minutes to collect adherent cells, namely CD14 + monocytes.

[0050] 2) CD14 + Monocytes were inoculated into RPMI-1640 medium containing 800 U / mL granulo-macrophage factor and 1000 U / mL interleukin-4 and incubated at 37°C, CO 2 After induction in an incubator with a concentration of 5% for 3-5 days, half of the medium was changed, and granule-macrophage factor and interleukin-4 were supplemented to maintain the concentration of granule-macrophage factor and interleukin-4 to obtain immature DC;

[0051] 3) Use PBS solution (PH=7.4) to adjust the concentration of immature DC cell...

Embodiment 2

[0054] The difference from Example 1 provided by the present invention is that in this example, the concentration of tumor necrosis factor-α is 10 ng / ml, and the concentration of interleukin-1 is 5 ng / ml.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a DC-based therapeutic glioma vaccine and a preparation method thereof. The preparation method includes the steps: (1) collecting immature DCs; (2) adding in glioma antigen peptides and the immature DCs for co-culture; (3) adding in tumor necrosis factor-alpha and interleukin or lipopolysaccharide for continuous culture for 7-13 days till the DCs are mature and loaded with the glioma antigen peptides. The DC-based therapeutic glioma vaccine is high in immunogenicity and capable of well regulating the body immunity mechanism for gliomas.

Description

technical field [0001] The invention relates to the fields of bioengineering and biomedicine, in particular to a DC-based therapeutic vaccine for glioma and a preparation method thereof. Background technique [0002] Glioma is a tumor derived from the neuroepithelium. It is the most common malignant tumor in the brain, accounting for about 40-50% of all intracranial tumors. It has become the mainstay of tumor treatment due to its high incidence, high recurrence rate, and high mortality rate. problem. Traditional treatment methods are mainly surgery and radiotherapy and chemotherapy to improve the survival rate of patients. However, total resection of gliomas located in important functional areas is difficult. Radiation therapy is the routine treatment for almost all types of glioma, but the efficacy evaluation is different. Except for medulloblastoma, which is highly sensitive to radiotherapy, and ependymoma, which is moderately sensitive, other types are not sensitive to ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/12A61K39/00A61P35/00C12N5/0784
Inventor 曾宪卓鲁菲
Owner SHEN ZHEN ISTEM REGENERATIVE MEDICINE SCI TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com